Articles by Chitra Sethi - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Chitra Sethi

Vetter Installs Six Automatic Packaging Lines at its New Facility

Jun 19, 2009

Vetter Pharma International (Ravensburg, Germany) has completed the installation of six automatic packaging lines at Vetter Secondary Packaging (VSP), the company?s new packaging services facility.

Three Shared Audit Models Tested at Rx-360 Consortium's Launch Meeting

Jun 17, 2009

The newly formed Rx-360 consortium had an impressive turnout of over 125 people at its launch meeting in Washington, DC, on June 5.

14 Years of Market Exclusivity Unnecessary, says FTC

Jun 16, 2009

A new report by FTC, entitled ?Follow-on Biologic Drug Competition,? examines whether the price of biologics is likely to be reduced by competition from FOBs.

BMS and ImClone Recall Erbitux

Apr 9, 2009

ImClone Systems, Inc. (Branchburg, NJ), and Bristol-Myers Squibb (BMS, New York, NY) voluntarily recalled 13 lots of their cancer drug Erbitux (cetuximab) after a report from a doctor?s office about a leaking cap on a vial of the biologic.

Buckle-Up Biopharma

BioPharm International's third annual salary survey finds out if the turbulent economic climate is taking its toll on the biopharmaceutical sector.
Jan 1, 2009

Will the global economic crisis affect your job? BioPharm International's third annual salary survey finds out.

Eli Lilly to Acquire ImClone for $6.5 Billion

Oct 6, 2008

Eli Lilly acquires Imclone

Eli Lilly in Talks to Acquire ImClone for $6.1 Billion

Oct 3, 2008

Eli Lilly (Indianapolis, In) is the mystery bidder "in advanced talks" to acquire ImClone Systems (New York, NY).

ImClone Rejects Bristol-Myers Offer

Sep 10, 2008

Biotechnology company ImClone Systems (New York, NY) has rejected the offer it received last month from its cancer drug partner Bristol-Myers (BMS, New York, NY) to acquire ImClone for $60 per share.

Bristol-Myers Offers $4.5 Billion for ImClone

Aug 4, 2008

Bristol-Myers Squibb has proposed to acquire its cancer drug partner ImClone Systems in an all-cash deal worth around $4.5 billion.

ADVERTISEMENT

ADVERTISEMENT

Click here